Betulonic Acid Inhibits HBV Replication via Modulating ERK1/2-HNF4α Axis
International Journal of Pharmacology · 21.10.2026 · 22 (6)
DOI: 10.31083/ijp50778 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 21.10.2026. Verfasst von Qianqian Xu und 9 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Anhui Province University Outstanding/Excellent Youth Research Project, Research Start-up Funding of Institute of Health and Medicine, Hefei Comprehensive National Science Center.
Abstract (Originalsprache)
Background
Chronic hepatitis B virus (HBV) infection continues to pose a significant global public health burden. Existing therapies achieve functional cures at limited rates and are complicated by problems including drug resistance and cumulative toxicity. Betulonic acid (Bet) is known for its anti-inflammatory, antibacterial, and antitumor activities. However, whether its antimicrobial effects extend to HBV infection remains unclear. Consequently, this study investigates the antiviral effects of Bet both in vitro and in vivo.
Methods
Bet effect on HBV replication and transcription was first investigated using Enzyme-Linked Immunosorbent Assay (ELISA) and real-time quantitative reverse transcription (RT-qPCR). Western blot and RNA-seq analyses were performed to elucidate the antiviral mechanism. Finally, animal experiments were conducted to assess the in vivo anti-HBV effect of Bet.
Results
In vitro experiments demonstrated that Bet significantly inhibited secretion of HBsAg and HBeAg, reduced HBV total RNA and pregenomic RNA levels, and exerted antiviral effects by modulating the extracellular signal-regulated MAP kinases (ERK1/2)-hepatocyte nuclear factor 4 alpha (HNF4α) axis. Concurrently, the reduction in serum HBV DNA copy number in infected mice confirmed the therapeutic efficacy of Bet against HBV infection in vivo.
Conclusion
These results demonstrate that Bet exhibits anti-HBV activity, which could inform new drug development strategies for HBV.
Förderung
- National Natural Science Foundation of China
- Anhui Province University Outstanding/Excellent Youth Research Project
- Research Start-up Funding of Institute of Health and Medicine, Hefei Comprehensive National Science Center
Zitieren
APA
Xu, Q., Ma, S., Pan, Y., Li, S., Zhu, Y., Wang, L., Chen, J., Liu, Y., Deng, M., & Zhao, B. (2026). Betulonic Acid Inhibits HBV Replication via Modulating ERK1/2-HNF4α Axis. International Journal of Pharmacology, 22(6). https://doi.org/10.31083/ijp50778
Vancouver
Xu Q, Ma S, Pan Y, Li S, Zhu Y, Wang L, et al. Betulonic Acid Inhibits HBV Replication via Modulating ERK1/2-HNF4α Axis. International Journal of Pharmacology. 2026;22(6). doi:10.31083/ijp50778
BibTeX
@article{Xu2026,
author = {Xu, Qianqian and Ma, Sien and Pan, Yan and Li, Shumin and Zhu, Yuting and Wang, Lulu and Chen, Jiawei and Liu, Yarong and Deng, Mengmeng and Zhao, Bao},
title = {Betulonic Acid Inhibits HBV Replication via Modulating ERK1/2-HNF4α Axis},
journal = {International Journal of Pharmacology},
year = {2026},
volume = {22},
number = {6},
doi = {10.31083/ijp50778}
}
EUVIMED